ArriVent BioPharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan '26 Jan 23, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	1,037	898	-	-	-
Enterprise Value	740	615	-	-	-
Last Close Price	25.20	26.64	-	-	-
PB Ratio	3.38	3.48	-	-	-
P/TBV Ratio	3.41	3.48	-	-	-
Debt / Equity Ratio	0	0.00	0.00	0.00	-
Quick Ratio	13.95	12.70	13.00	19.60	20.64
Current Ratio	14.90	13.14	13.76	21.85	23.63
Return on Equity (ROE)	-51.84%	-39.36%	-42.57%	-34.22%	-
Return on Assets (ROA)	-32.78%	-26.91%	-26.95%	-20.42%	-
Return on Capital Employed (ROCE)	-53.30%	-36.60%	-49.20%	-21.20%	-28.10%
Earnings Yield	-14.51%	-8.97%	-	-	-
Buyback Yield / Dilution	-52.43%	-1369.88%	-67.64%	-79.57%	-

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q